| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-05-0404 |
| P698 | PubMed publication ID | 16024606 |
| P50 | author | Maureen Murtaugh | Q42613771 |
| Carol Sweeney | Q46579106 | ||
| Martha L Slattery | Q87148386 | ||
| Jennifer S Herrick | Q87148394 | ||
| Roger K Wolff | Q96140937 | ||
| Theodore R Levin | Q96185266 | ||
| Wade S. Samowitz | Q112111709 | ||
| P2093 | author name string | Hans Albertsen | |
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microsatellite | Q265193 |
| P304 | page(s) | 6063-6069 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers | |
| P478 | volume | 65 |
| Q64235538 | A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update |
| Q34293192 | A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps |
| Q34066685 | A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. |
| Q37283757 | A comparison of colon and rectal somatic DNA alterations |
| Q37017721 | A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. |
| Q35187723 | A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer |
| Q33808550 | A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers |
| Q33541323 | A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes |
| Q35584153 | A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy |
| Q35071477 | A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome |
| Q33945376 | A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. |
| Q37161304 | AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. |
| Q38798435 | Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer |
| Q92628956 | Alterations in signaling pathways that accompany spontaneous transition to malignancy in a mouse model of BRAF mutant microsatellite stable colorectal cancer |
| Q91557781 | An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas |
| Q37400731 | Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis. |
| Q37708019 | Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. |
| Q89843964 | Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies |
| Q34759064 | Association between molecular subtypes of colorectal cancer and patient survival |
| Q40198390 | Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. |
| Q36868636 | Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147 |
| Q37170000 | Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women |
| Q33740175 | Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study |
| Q37776505 | BRAF Mutation Testing in Colorectal Cancer |
| Q34206112 | BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity |
| Q51014855 | BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. |
| Q37216950 | BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. |
| Q34286030 | BRAF inactivation drives aneuploidy by deregulating CRAF |
| Q91437947 | BRAF molecular testing in cytopathology: Implications for diagnosis, prognosis, and targeted therapeutics |
| Q26772276 | BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies |
| Q42844593 | BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age. |
| Q37615625 | BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer |
| Q33796513 | BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis |
| Q40823445 | BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer |
| Q36306276 | BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics |
| Q21245742 | BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status |
| Q33906044 | BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome |
| Q33726858 | BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer |
| Q28543370 | BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications |
| Q94602693 | BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer |
| Q54325213 | BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. |
| Q34782265 | BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome |
| Q33615076 | BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. |
| Q35075820 | BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. |
| Q27852942 | BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q37609130 | Biomarkers in precision therapy in colorectal cancer. |
| Q36153320 | Biomarkers, bundled payments, and colorectal cancer care |
| Q38709785 | Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies |
| Q52666764 | CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. |
| Q35583180 | Cancer immunology--analysis of host and tumor factors for personalized medicine |
| Q34092337 | Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry |
| Q34292820 | Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia |
| Q92451360 | Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients |
| Q34460444 | Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers |
| Q58608206 | Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study |
| Q27692120 | Clinical implications of BRAF mutation test in colorectal cancer |
| Q37708040 | Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer |
| Q88990765 | Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer |
| Q33875090 | Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing |
| Q64123101 | Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis |
| Q36463826 | Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. |
| Q42690646 | Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study |
| Q64975299 | Clinicopathological Significance of BRAFV600E Mutation in Colorectal Cancer: An Updated Meta-Analysis. |
| Q34010171 | Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways |
| Q38652194 | Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation |
| Q88780422 | Colorectal Cancer: Why Does Side Matter? |
| Q37146010 | Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis |
| Q39456150 | Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients |
| Q58762177 | Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy |
| Q39334444 | Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm |
| Q38412549 | Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor |
| Q33291970 | Colorectal carcinogenesis: road maps to cancer |
| Q34642007 | Colorectal carcinoma: Pathologic aspects |
| Q35579056 | Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages |
| Q37157958 | Colorectal clinical trials: what is on the horizon? |
| Q37139194 | Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis |
| Q36086848 | Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer |
| Q27853216 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. |
| Q35082216 | Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer |
| Q43805357 | Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer |
| Q54297781 | Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors. |
| Q57287641 | Comment on "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer" |
| Q28485279 | Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics |
| Q27852136 | Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer |
| Q37327430 | Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors |
| Q91876747 | Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients |
| Q35001203 | Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer |
| Q52976044 | Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. |
| Q36075933 | CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. |
| Q24597977 | CpG island methylation in colorectal cancer: past, present and future |
| Q79988265 | CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma |
| Q35760749 | CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies |
| Q34177058 | CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China. |
| Q35710965 | CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer |
| Q41066289 | CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers |
| Q37185561 | CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer |
| Q37261842 | CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. |
| Q33829763 | Current status of gene expression profiling to assist decision making in stage II colon cancer |
| Q37185554 | Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer |
| Q37190177 | DDA1 promotes stage IIB-IIC colon cancer progression by activating NFκB/CSN2/GSK-3β signaling |
| Q36613849 | DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer |
| Q35051119 | DNA methylation predicts recurrence from resected stage III proximal colon cancer |
| Q33517453 | DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. |
| Q89717427 | DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation |
| Q34986042 | Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer |
| Q39433444 | Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis |
| Q34760933 | Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping |
| Q35721438 | Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique |
| Q90284927 | Determination of Cut Point in the Age of Colorectal Cancer Diagnosis Using a Survival Cure Model |
| Q36189476 | Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization |
| Q58806326 | Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer |
| Q26768471 | Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review |
| Q40428222 | Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location |
| Q24652600 | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity |
| Q50001605 | Distinct histopathological characteristics in colorectal submucosal invasive carcinoma arising in sessile serrated adenoma/polyp and conventional tubular adenoma. |
| Q34805590 | Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis |
| Q34627605 | EGFR Signaling in Colorectal Carcinoma |
| Q35873526 | ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. |
| Q35146186 | Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition |
| Q34487177 | Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers |
| Q38212699 | Establishing a biological profile for interval colorectal cancers. |
| Q37151106 | Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. |
| Q35855515 | Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample |
| Q40014365 | Evolving role of cetuximab in the treatment of colorectal cancer |
| Q92231021 | Exploring the best treatment options for BRAF-mutant metastatic colon cancer |
| Q43572389 | Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer |
| Q35760876 | Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. |
| Q42203684 | FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer |
| Q80548201 | Family history and survival after colorectal cancer diagnosis |
| Q33625221 | Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases |
| Q38786707 | From tumour heterogeneity to advances in precision treatment of colorectal cancer |
| Q47673133 | Gastrointestinal Malignancy: Genetic Implications to Clinical Applications |
| Q51896941 | Genetic alterations of K‐ras may reflect prognosis in stage III colon cancer patients below 60 years of age |
| Q40091410 | Genetic and epigenetic changes in colon cancer |
| Q42257482 | Genetic and epigenetic events generate multiple pathways in colorectal cancer progression |
| Q27016019 | Genetic and epigenetic traits as biomarkers in colorectal cancer |
| Q35143808 | Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis |
| Q37523207 | Genetic prognostic and predictive markers in colorectal cancer |
| Q38191462 | Genetic unraveling of colorectal cancer |
| Q31012680 | Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? |
| Q26739052 | Genomic diversity of colorectal cancer: Changing landscape and emerging targets |
| Q33866105 | Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term |
| Q42843688 | Heredity and DNA methylation in colorectal cancer. |
| Q35677169 | High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort |
| Q54331482 | High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer. |
| Q60939319 | How the V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications |
| Q90720640 | Human Colorectal Cancer from the Perspective of Mouse Models |
| Q90088006 | Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer |
| Q35527097 | Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms |
| Q41127026 | Immunoscore in mismatch repair-proficient and -deficient colon cancer. |
| Q34628085 | Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer |
| Q64059301 | Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series |
| Q37563971 | Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. |
| Q35037258 | Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. |
| Q37619856 | Important molecular genetic markers of colorectal cancer. |
| Q47932420 | Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. |
| Q35012020 | Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases |
| Q37632196 | Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. |
| Q58215000 | Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures |
| Q38417379 | Is BRAF mutation associated with interval colorectal cancers? |
| Q38406679 | Is KRAS mutation associated with interval colorectal cancers? |
| Q36213070 | Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype |
| Q35098287 | KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer |
| Q58966086 | KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression |
| Q33693309 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). |
| Q27851616 | KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. |
| Q33550512 | Lessons from Lynch syndrome: a tumor biology-based approach to familial colorectal cancer. |
| Q35000837 | Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome). |
| Q46255928 | Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma |
| Q37407802 | Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype |
| Q37987828 | Lynch syndrome: clinical, pathological, and genetic insights |
| Q29615542 | MAP kinase signalling pathways in cancer |
| Q36413436 | MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. |
| Q34692175 | MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland. |
| Q24598640 | Markers of resistance to anti-EGFR therapy in colorectal cancer |
| Q37948057 | Mechanisms of aneuploidy induction by RAS and RAF oncogenes |
| Q37360222 | Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation |
| Q39927458 | MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples |
| Q42776992 | Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development |
| Q42672451 | Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. |
| Q54631097 | Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. |
| Q40864425 | MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. |
| Q37075412 | Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication |
| Q35191237 | Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer |
| Q33954707 | Microsatellite instability and survival in rectal cancer |
| Q35126713 | Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability |
| Q40975682 | Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer |
| Q34362289 | Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies |
| Q39381552 | Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective |
| Q91599765 | Molecular Profiles Guide Colorectal Cancer Treatment |
| Q34976621 | Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status |
| Q35737549 | Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution |
| Q37708015 | Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. |
| Q64071667 | Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients |
| Q39308037 | Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates |
| Q59329900 | Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study |
| Q36329300 | Molecular classification and correlates in colorectal cancer |
| Q37632108 | Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia |
| Q34665492 | Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes |
| Q24289344 | Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease |
| Q26785725 | Molecular phenotypes of colorectal cancer and potential clinical applications |
| Q36843773 | Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. |
| Q33813216 | Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). |
| Q36594927 | Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyposis. |
| Q34755943 | Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value |
| Q35082873 | Mutational analysis and clinical correlation of metastatic colorectal cancer |
| Q54591533 | Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. |
| Q33883829 | Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction |
| Q40490322 | No association of CpG island methylator phenotype and colorectal cancer survival: population-based study. |
| Q35351133 | Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer |
| Q37728856 | Oncogenic mutations as predictive factors in colorectal cancer |
| Q48192463 | Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity |
| Q88413794 | Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience |
| Q35651134 | PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation |
| Q34778710 | PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival |
| Q37236257 | PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival |
| Q39041163 | Phenotypic profiling of Raf inhibitors and mitochondrial toxicity in 3D tissue using biodynamic imaging. |
| Q26795558 | Precision medicine in colorectal cancer: the molecular profile alters treatment strategies |
| Q38885822 | Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma |
| Q27347219 | Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics. |
| Q39453559 | Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment |
| Q37132653 | Predictive and prognostic factors in colorectal cancer: a personalized approach |
| Q83529174 | Predictive and prognostic markers in colorectal cancer |
| Q35729861 | Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 |
| Q35663416 | Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma |
| Q36346491 | Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. |
| Q92125806 | Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis |
| Q33895573 | Primary and acquired resistance to biologic therapies in gastrointestinal cancers |
| Q34472453 | Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer |
| Q89529095 | Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges |
| Q35583987 | Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery |
| Q33620070 | Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients |
| Q37287501 | Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer |
| Q37340755 | Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study |
| Q51603737 | Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. |
| Q43860851 | Prognostic marker profiles for risk of distant metastases in colorectal cancer |
| Q35874805 | Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer |
| Q35137525 | Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma |
| Q37173288 | Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. |
| Q34553646 | Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. |
| Q35012132 | Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer |
| Q37132721 | Prognostic value of colorectal cancer biomarkers. |
| Q57491315 | Prognostic value of the combination of microsatellite instability and mutation in colorectal cancer |
| Q34703562 | Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer |
| Q53337445 | Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. |
| Q54505360 | Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status. |
| Q27684109 | Pyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors |
| Q28074175 | RAS and BRAF in metastatic colorectal cancer management |
| Q38707761 | RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). |
| Q55358017 | RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. |
| Q49887919 | Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors |
| Q34657323 | Review of histopathological and molecular prognostic features in colorectal cancer |
| Q48160519 | Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases |
| Q34266707 | Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives |
| Q34458644 | SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features |
| Q33882664 | SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer |
| Q38473801 | Serrated neoplasia-role in colorectal carcinogenesis and clinical implications |
| Q36023417 | Serrated pathway colorectal cancer in the population: genetic consideration |
| Q42769381 | Serrated pathway: alternative route to colorectal cancer |
| Q37355802 | Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study |
| Q87702900 | Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience |
| Q33857897 | Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer |
| Q36761405 | Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers |
| Q39173195 | Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations |
| Q35550879 | T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. |
| Q38100162 | Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? |
| Q38239612 | Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies |
| Q92821183 | Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis |
| Q39456735 | Targeting the Microenvironment in Advanced Colorectal Cancer |
| Q36177993 | Telomerase activity in colorectal cancer, prognostic factor and implications in the microsatellite instability pathway |
| Q37945533 | The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? |
| Q54343834 | The BRAF mutation is associated with the prognosis in colorectal cancer. |
| Q33986683 | The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy |
| Q92081786 | The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer |
| Q38825575 | The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms |
| Q89519692 | The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer |
| Q36873811 | The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer |
| Q34442771 | The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis |
| Q33679614 | The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer |
| Q36582552 | The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer |
| Q35151786 | The role of the CpG island methylator phenotype on survival outcome in colon cancer |
| Q34660196 | The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator. |
| Q92326335 | Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study |
| Q26827212 | Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF |
| Q36790917 | Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model |
| Q54389429 | Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. |
| Q42111689 | Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer |
| Q34551974 | Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review |
| Q46590868 | Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology |
| Q28287782 | Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants |
| Q90697948 | Upregulation of microRNA-31 is associated with poor prognosis in patients with advanced colorectal cancer |
| Q36656389 | Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. |
| Q36561520 | VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer |
| Q31045418 | Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method |
| Q36081402 | Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer |
| Q53581884 | [Molecular pathology of colorectal cancer]. |
| Q84919923 | [Serrated pathway of colorectal carcinogenesis] |
| Q54560727 | [Serrated precursor lesions]. |
| Q47128749 | microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer |
| Q37379089 | p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis |
Search more.